LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, has received approximately 163,000 shares of common stock in ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) in exchange for its 19.1% ownership position in SynthRx, Inc., following the completion of ADVENTRX’s previously announced acquisition of SynthRx. The last sale price of ADVENTRX shares on the NYSE Amex on April 8, 2011 was $2.34.
